A Randomized, Phase IIIb, Two-period , Double-blind, Two-treatment, Chronic-dosing (7 Days), Single-center Crossover Study to Evaluate the Treatment Effect of PT003 on Cardiovascular Hemodynamics in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease, Compared With Placebo
Phase of Trial: Phase III
Latest Information Update: 25 May 2018
At a glance
- Drugs Formoterol/glycopyrrolate (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacodynamics
- Sponsors Pearl Therapeutics
- 15 May 2018 Planned End Date changed from 3 May 2019 to 18 Oct 2019.
- 15 Mar 2017 Planned End Date changed from 1 Feb 2018 to 3 May 2019.
- 15 Mar 2017 Planned primary completion date changed from 1 Feb 2018 to 3 May 2019.